(Q38119474)

29 August 2017

title

"Bright spotty lesions" on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis (English)

1 reference

29 August 2017

0 references

1 reference

Tadahiro Yonezu

1 reference

29 August 2017

Shoichi Ito

1 reference

29 August 2017

Masahiro Mori

1 reference

29 August 2017

Yoshitsugu Ogawa

1 reference

29 August 2017

Takahiro Makino

1 reference

29 August 2017

Akiyuki Uzawa

1 reference

29 August 2017

Satoshi Kuwabara

1 reference

29 August 2017

publication date

4 July 2013

1 reference

Multiple Sclerosis Journal

29 August 2017

published in

1 reference

29 August 2017

1 reference

29 August 2017

1 reference

29 August 2017

page(s)

331-337

1 reference

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458513495581

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513495581

Immunosuppressive therapy is more effective than interferon in neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513495581

Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513495581

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513495581

Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513495581

Failure of natalizumab to prevent relapses in neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513495581

Does natalizumab therapy worsen neuromyelitis optica?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513495581

Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513495581

Neuromyelitis optica: new findings on pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513495581

Brain magnetic resonance imaging findings in relapsing neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513495581

Brain abnormalities in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513495581

Conventional brain MRI in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513495581

"Cloud-like enhancement" is a magnetic resonance imaging abnormality specific to neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513495581

Revised diagnostic criteria for neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513495581

Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513495581

Preferential spinal central gray matter involvement in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458513495581

21 January 2018

Identifiers

DOI

10.1177/1352458513495581

1 reference

29 August 2017

1 reference